pharma · Encephalitis · Japanese Encephalitis
Valneva USA
Valneva Austria GmbH
Valneva Austria is a pharma organization headquartered in Wien, AT. Primary therapeutic focus areas include Encephalitis, Japanese Encephalitis. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent
Bethesda, USA HQ
2017 Founded
9 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Bethesda, USA
- Founded
- 2017
- Employees
- 9
- Programs
- 2
- Drugs
- 1
- Patents
- 0
IXIARO
Phase 3 · mab · Japanese Encephalitis
IXIARO for Japanese Encephalitis is a Phase 3 program (mab) at Valneva Austria GmbH with 1 ClinicalTrials.gov record(s).
Internal code IC51-325
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Valneva Austria GmbH
- Phase
- Phase 3
- Modality
- mab
- Indication
- Japanese Encephalitis
- Status
- completed
- Trials
- 1